Prednisone Therapy Duration and Tapering in Giant Cell Arteritis

Initial Glucocorticoid Regimen

Begin oral prednisone at 40–60 mg/day (≈1 mg/kg, max 60 mg) immediately upon clinical suspicion and maintain for about 1 month until symptoms resolve and inflammatory markers normalize. [1][2]
In patients presenting with acute visual symptoms (vision loss or amaurosis fugax), give intravenous methylprednisolone 0.25–1 g/day for 3 days before switching to oral prednisone 60 mg/day. [1][2]

Months 0–3: Reduce the initial dose to 15–20 mg/day within 2–3 months. [1][2]
Months 3–12: Continue a gradual taper so that the dose is ≤5 mg/day by month 12. [1][2]
Beyond 12 months: Most patients need continued low‑dose therapy (typically a total of ≥2 years) before complete discontinuation is feasible. 1

Relapses are uncommon (<3 %) while the prednisone dose remains >20 mg/day, but the risk rises markedly when the dose falls below 20 mg/day and especially below 5 mg/day. 1
Each relapse generally requires reinstating or increasing the glucocorticoid dose, leading to higher cumulative exposure and a greater likelihood of adverse events. 1

Adding tocilizumab 162 mg subcutaneously weekly to prednisone permits a 26‑week taper (instead of ≥52 weeks with prednisone alone), substantially lowering cumulative glucocorticoid exposure. 1

The EULAR panel, based on expert consensus rather than high‑quality trial data, states that “it usually takes about 2 years or more before glucocorticoids can be stopped.” This reflects a consensus‑level recommendation. 1
Traditional protocols (also endorsed by EULAR) recommend a total glucocorticoid course of 1–2 years or longer. 1
Rapid taper protocols designed for clinical trials should not be used in routine practice without a glucocorticoid‑sparing agent, as they intentionally generate high relapse rates. 1
Tapering below 5 mg/day within the first year should be avoided because this threshold marks a critical inflection point for relapse risk. 1

Prednisone‑only patients: Plan a minimum total treatment duration of 18–24 months; taper to 15–20 mg/day by month 3 and to ≤5 mg/day by month 12; then continue low‑dose prednisone (2.5–5 mg/day) for an additional 6–12 months before attempting discontinuation. [1][2]
Patients receiving tocilizumab + prednisone: Follow a 26‑week prednisone taper as outlined in published protocols; continue tocilizumab for 12 months regardless of prednisone duration. 1

The European League Against Rheumatism (EULAR) recommends considering the administration of 0.25–1 g of methylprednisolone intravenously daily for up to 3 consecutive days in patients with giant cell arteritis (GCA) who present with acute vision loss or transient vision loss 3, 4, 5, 6, 7
Pulse therapy with methylprednisolone IV should be limited to patients with complicated GCA, particularly those with vision-related symptoms 3, 4, 8

Acute vision loss is a symptom that justifies the use of methylprednisolone IV 3, 4, 5, 6, 7
Transient vision loss is a symptom that justifies the use of methylprednisolone IV 3, 4, 5, 6, 7
Double vision is a symptom that may justify the use of methylprednisolone IV 6, 7
Anterior ischemic optic neuropathy is a symptom that may justify the use of methylprednisolone IV 6, 7
Central retinal artery occlusion is a symptom that may justify the use of methylprednisolone IV 6, 7

For patients with visual symptoms, initiate methylprednisolone IV 0.25–1 g/day for 3 days, followed by oral prednisone 60 mg/day 3, 4, 5, 6, 7
For patients without visual symptoms, start directly with oral glucocorticoids 40-60 mg/day of prednisone 3, 4, 5, 6, 7, 8

Once remission is achieved, reduce the glucocorticoid dose to 15-20 mg/day within 2-3 months, and then to ≤5 mg/day after 1 year 3, 4, 5, 6, 7, 8
Most patients require approximately 2 years or more before completely stopping glucocorticoids 5, 8

The EULAR 2018 guidelines recognize that there are only low-quality retrospective clinical data supporting the use of methylprednisolone IV pulses for visual symptoms 3, 4, 5
The strength of evidence for the use of methylprednisolone IV pulses is limited by the lack of high-quality randomized controlled trials 3, 4, 8

Do not delay oral glucocorticoid treatment while waiting for access to IV therapy 3, 4, 8
Do not use methylprednisolone IV in uncomplicated GCA cases without visual symptoms 3, 4, 8
Do not reduce glucocorticoids too quickly, as this increases the risk of relapse 3, 4, 5, 8

Consider tocilizumab or methotrexate as glucocorticoid-sparing agents in patients with refractory/recurrent disease or at higher risk of glucocorticoid-related adverse effects 3, 4, 5, 8
Implement osteoporosis prophylaxis in all patients with prolonged glucocorticoid therapy 9